ParkerVision, Inc. reported financial and operating results for the year ended December 31, 2025, including a net loss of $7.4 million or $0.06 per common share, improved from $14.5 million or $0.16 per share in 2024, primarily due to changes in the fair value of contingent payment obligations. The filing includes updates on expedited CAFC appeal in the Qualcomm case and postponement of the MediaTek trial.
Key takeaways
Net loss of $7.4 million or $0.06 per common share for year ended December 31, 2025, vs. $14.5 million or $0.16 per share for 2024
Cash and cash equivalents of $4.4 million and $2.3 million in working capital as of December 31, 2025
CAFC granted expedited schedule for ParkerVision v. Qualcomm appeal (case no. 26-1033), with briefings by March 23, 2026
MediaTek patent infringement trial in Western District of Texas postponed from March 20, 2026 pending expert reports
Sold 21.2 million common shares at $0.21 per share in November 2025 for $4.5 million gross proceeds
Issued 3.2 million common shares at $0.21 per share in March 2026 to satisfy $0.67 million convertible note maturities